CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.
Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated 100% coverage (100% inhibition at less than or equal to 1 microgram/ml) against these strains. Activity was slightly better than telithromycin (MIC90 of 0.25 microgram/ml for both; range of less than or equal to 0.008 to 1 for CEM-101 vs. less than or equal to 0.06 to 2 for telithromycin) and at least four-fold better than linezolid (MIC90 of 1 microgram/ml) or vancomycin (MIC90 of less than or equal to 1 microgram/ml). The study will be presented during a poster session on October 30.
CEM-101 is a new fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, as well as non-bacterial pathogens such as Plasmodium falciparum. The compound recently completed a Phase 1 clinical trial and is in preparation for a Phase 2 trial in moderate to moderately-severe community-acquired bacterial pneumonia.
"The rise of multidrug-resistant organisms has become an increasing public health issue, particularly for vulnerable patient populations including those with challenging respiratory infections," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals. "New medications are needed that are safe and effective against these difficult-to-treat pathogens. We believe that the growing database showing the potency and broad-spectrum activity of CEM-101, not only against the pneumococcal strains presented here, but against a variety of other pathogens, indicates the potential of CEM-101 as a future go-to antibiotic for clinicians."
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.
Media Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 Robert.firstname.lastname@example.org Tony Russo, Ph.D. Russo Partners, LLC (212) 845-4251 Tony.email@example.com
SOURCE Cempra Pharmaceuticals
|SOURCE Cempra Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved